APPENDICES. A systematic review and economic model of the ...

252
Appendix 12
Core symptoms Educational performance Quality of life Adverse events
Not reported Not reported SERS (parents): number of side-effects
MPH 0.2: 5.7 (3.5)
MPH 0.4: 5.8 (3.5)
Placebo: 5.7 (3.7)
F = 0.20, NS
SERS (parents): mean severity rating
MPH 0.2: 3.2 (1.7)
MPH 0.4: 3.3 (1.8)
Placebo: 3.5 (1.8)
F = 1.77, NS
SERS (teachers): number of side-effects
MPH 0.2: 4.2 (2.8)
MPH 0.4: 4.1 (3.0)
Placebo: 4.5 (2.9)
F = 1.15, NS
SERS (teachers): mean severity rating
MPH 0.2: 3.3 (1.9)
MPH 0.4: 3.1 (1.9)
Placebo: 3.8 (2.0)
F = 7.74, p < 0.001. Pairwise comparison:
H/L > P
CPRS-R: total problems (mean, SD)
Baseline: 53.3 (19.9), n = 161, range: 7–96
MPH 0.2: 34.9 (19.9)
MPH 0.4: 33.6 (20.4)
Placebo: 42.2 (21.2);
F = 18.88, p < 0.001. Pairwise comparison:
L/H > Placebo
(p = placebo, L = low dose, H = high dose)
CPRS-R: hyperactivity index
Baseline: 17.8 (6.0), n = 161, range: 2–30
MPH 0.2: 11.7 (6.4)
MPH 0.4: 11.1 (6.7)
Placebo: 14.3 (6.8)
F = 21.13, p < 0.001. L/H > P
CPRS-R: impulsivity–hyperactivity
Baseline: 7.8 (3.2), n = 161, range: 0–17
MPH 0.2: 5.1 (3.0)
MPH 0.4: 4.8 (3.1)
Placebo: 6.6 (3.4)
F = 28.16, p < 0.001. Pairwise comparison: L/H > P
CTRS-R: total problems
Baseline: 39.2 (16.8), n = 161, range: 5–81
MPH 0.2: 25.7 (16.3)
MPH 0.4: 21.3 (14.7)
Placebo: 34.0 (19.4)
F = 40.62, p < 0.001. Pairwise comparison: L/H > P,
H > L
CTRS-R: hyperactivity index
Baseline: 16.4 (7.2), n = 161, range: 0–31
MPH 0.2: 9.9 (6.6)
MPH 0.4: 8.4 (6.3)
Placebo: 13.7 (7.6)
F = 44.47, p < 0.001. Pairwise comparison: H/L > P
continued